- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
CBLC Antibody (C-term)Purified Rabbit Polyclonal Antibody (Pab)
| Country | United States
Ordering Information
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| AP1258a | 0.1 mg 400 ul | In Stock | $ 255.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
CBLC Antibody (C-term) - Product info | |
| Application | IHC, WB
|
| Primary Accession | Q9ULV8 |
| Reactivity | Human |
| Concentration | 0.25 mg/ml |
| Isotype | Rabbit Ig |
| Calculated MW | 52456 Da |
CBLC Antibody (C-term) - Additional info | |
| Gene ID 23624 | |
| Other Names CBLC; CBL3; RNF57; Signal transduction protein CBL-C; RING finger protein 57; SH3-binding protein CBL-3; SH3-binding protein CBL-C | |
| Target/Specificity This CBLC antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 172~202 amino acids from the C-terminal region of human Cbl-c. | |
| Dilution IHC~~1:50~100 WB~~1:100~500WB~~1:1000 | |
| Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. | |
| Precautions CBLC Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. | |
CBLC Antibody (C-term) - Protein Information | |
| Name CBLC | |
| Synonyms CBL3, RNF57 | |
| Function Regulator of EGFR mediated signal transduction. | |
| Cellular Location Nucleus (Potential). | |
| Tissue Location Ubiquitous. | |
CBLC Antibody (C-term) - Related products
AP1257a: CBLC Antibody (N-term)
AP1258a: CBLC Antibody (C-term)
DC05882: Human CBLC cDNA Clone
CBLC Antibody (C-term) - Application data
-
Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.
-
CBLC Antibody (R439) (Cat. #AP1258a) western blot analysis in K562 cell line lysates (35ug/lane).This demonstrates the CBLC antibody detected the CBLC protein (arrow).
CBLC Antibody (C-term) - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
Cbl proteins are a family of ubiquitin protein ligases (E3s) that negatively regulate signaling by targeting activated tyrosine kinases for degradation. Cbl- c is the most recently cloned member of the Cbl proteins and is expressed only in epithelial cells (the other Cbl proteins are ubiquitously expressed). Cbl-c, like the other mammalian Cbl proteins, can ubiquitinate the activated EGFR and target it for degradation. Through interactions with proteins containing SRC homology-2 (SH2) and SH3 domains, CBL proteins modulate downstream cell signaling.
REFERENCES
Strausberg, R.L., et al., Proc. Natl. Acad. Sci. U.S.A. 99(26):16899-16903 (2002). Keane, M.M., et al., Oncogene 18(22):3365-3375 (1999). Kim, M., et al., Gene 239(1):145-154 (1999).